Compare CZWI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | CCCC |
|---|---|---|
| Founded | 1938 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.7M | 177.4M |
| IPO Year | N/A | 2020 |
| Metric | CZWI | CCCC |
|---|---|---|
| Price | $18.83 | $1.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 61.6K | ★ 1.4M |
| Earning Date | 01-26-2026 | 02-27-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 8.71 | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $60,377,000.00 | $30,108,000.00 |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $9.42 | N/A |
| P/E Ratio | $12.96 | ★ N/A |
| Revenue Growth | ★ 1.35 | N/A |
| 52 Week Low | $12.69 | $1.09 |
| 52 Week High | $19.11 | $3.65 |
| Indicator | CZWI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 57.76 | 43.91 |
| Support Level | $18.10 | $1.74 |
| Resistance Level | $19.11 | $1.90 |
| Average True Range (ATR) | 0.48 | 0.12 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 83.23 | 40.56 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short- term investments; and funds provided from operations.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.